SY-1425, AZACITIDINE clinical trials

A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This study is testing a new drug, SY-1425, for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers are looking at how well it works, especially for patients with specific genetic markers, and if it's safe when used alone or with other medicines.